TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03748888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: An antenatal physical activity (APA) programme will be designed for participants in the exercise group.~The APA will last for 20-24 weeks. Participants in the EG must enrol in the APA between their 12-16 weeks of gestation.~The APA programme has a frequency of three times a week, which involves aerobic, strength and stretching exercises. The intensity of the APA programme is individually calculated for each participant based on their pre-pregnancy fitness level. Single sessions of the APA programme last 50-60min.
Study: NCT03978520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Capsule; Oral
Study: NCT02411773

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2-4 placebo pills will be given out prior to each exercise or stretching session.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2-4 placebo pills will be given out prior to each exercise or stretching session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
Study: NCT00372619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally or IT age based dosage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT02411773

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control to Exercise (Stretching)
Description: Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control to Exercise (Stretching)
Description: Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
Study: NCT00372619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT03978520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for elsubrutinib
Description: Capsule; Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for elsubrutinib
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for upadacitinib
Description: Film-coated tablet; Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for upadacitinib
Description: Film-coated tablet; Oral
Study: NCT02418364

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo reflexology treatment
Description: Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology treatment
Description: Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
Study: NCT03103737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) and Reminiscence Intervention
Description: First and third sessions are dedicated to remember positive and meaningful personal experiences. Second and fourth sessions are oriented to positive emotions by the use of VR. Participants can choose the virtual environment to work with.
Study: NCT01288105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom \>95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with \<95% stent strut coverage will receive perioperative bridging.
Study: NCT00667069

Intervention type: DRUG
Group type: OTHER
Intervention: triptorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: 3-dimensional conformal radiation therapy
Study: NCT01364948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil application
Description: Four ml coconut oil application twice daily for first week

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No oil application
Description: Oil application was not done
Study: NCT03733132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Metformin treatment of 2500mg for 10 months in the Metformin group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo treatment of identical tablets to metformin group
Study: NCT00372619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT02220153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Intravenous 1
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Intravenous 2
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Intravenous 3
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion
Study: NCT00667069

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study: NCT02233647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
Study: NCT02220153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Intravenous 4
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Intravenous 5
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Subcutaneous 1
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Subcutaneous 2
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: * Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous Placebo
Description: * Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: subcutaneous infusion
Study: NCT02233647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
Study: NCT01652612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: 8 cmH2O PEEP throughout the period of OLV and 2nd TLV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: 8 cmH2O PEEP throughout the period of OLV and 2nd TLV
Study: NCT00755092

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Doula
Description: Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Doula
Description: Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
Study: NCT02817256

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins and Minerals
Description: Multivitamins and Minerals supplementation
Study: NCT04579250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF0103-00-VP (H10ssF-6473)
Description: The vaccine is composed of the haemagglutinin (HA) stem domain from A/Jiangxi/IPB13/2013 (H10N8) influenza genetically fused to the ferritin protein from H. pylori. Purified H10ssF-6473 displays eight well-formed HA trimers that antigenically resemble the native H10 stem viral spikes.
Study: NCT01356264

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multimodal prehabilitation
Description: multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
Study: NCT02307604

Intervention type: GENETIC
Intervention: Tumour markers testing
Study: NCT03458403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motions during gastroscopy
Description: Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for. The endoscope is removed halfway up the esophagus and inserted into the pylorus to the descending duodenum. The gesture is repeated three times.
Study: NCT00487994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
Study: NCT02068664

Intervention type: BEHAVIORAL
Intervention: prism adaptation treatment
Description: Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
Study: NCT03934411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: The subjects will orally ingest 100 mg tramadol retard actavis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will orally ingest 100 mg calcium powder
Study: NCT02819050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: Nasal Continuous Positive Airway Pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NCPAP
Description: Nasal Continuous Positive Airway Pressure
Study: NCT02169700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic compression. Dry Needling
Description: Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ischemic compression. Dry Needling
Description: Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
Study: NCT02684617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
Study: NCT02567916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT02258698

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
Study: NCT04342897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127804
Description: Administered IV
Study: NCT00487994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and atorvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
Study: NCT04342897

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT01699204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel exhaust
Description: A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel exhaust
Description: A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Filtered air
Description: A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
Study: NCT02684617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinaciclib
Description: dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
Study: NCT03322878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium SO4
Description: The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium SO4
Description: The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
Study: NCT02684617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinaciclib
Description: dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinaciclib
Description: dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
Study: NCT00090779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/ tenofovir disoproxil fumarate
Description: once daily
Study: NCT03322878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium SO4
Description: The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
Study: NCT00691418

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: docosahexaenoic acid (DHA)
Description: 600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once per day starting at 22-24 weeks gestation until delivery.
Study: NCT04166175

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: botox injection in intersphincteric space
Description: injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position